"Bullfrog neck," a unique morphologic trait in HIV lipodystrophy: Case series and review of the literature

Archives of Dermatology

Volumn 146, Issue 11, 2010, Pages 1279-1282

  Tierney, Emily P ^a,b   Hanke, C William ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Laser and Skin Surgery Center of Indiana   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; RITONAVIR; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CASE REPORT; DIABETES MELLITUS; DRUG EFFICACY; DRUG WITHDRAWAL; FACE DYSMORPHIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HYPERLIPIDEMIA; LIPOATROPHY; MALE; MORPHOLOGICAL TRAIT; PRIORITY JOURNAL; QUALITY OF LIFE;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; NECK; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 78349237442     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.341     Document Type: Article

References (24)

1. Waters L, Nelson M. Long-term complications of antiretroviral therapy: lipoatrophy. Int J Clin Pract. 2007;61(6):999-1014.
2. Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis. 2007;7(12):787-796.
3. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351(9119):1881-1883. (Pubitemid 28279721)
4. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS. 1999;13(16):2311-2312.
5. Stankov MV, Lücke T, Das AM, Schmidt RE, Behrens GM; German Competence Network HIV/AIDS. Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors. Antivir Ther. 2007;12(2):205-216.
6. Gentil C, Le Jan S, Philippe J, et al. Is oxygen a key factor in the lipodystrophy phenotype? Lipids Health Dis. 2006;5:27.
7. Cherry CL, Lal L, Thompson KA, et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr. 2005;38(3):263-267.
8. Sutinen J, Yki-Järvinen H. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab. 2007;292(3):E687-E692.
9. Haugaard SB, Andersen O, Vølund A, et al. Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Clin Endocrinol (Oxf ). 2005;62(3):354-361.
10. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(7):F51-F58.
11. Mallon PW. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy. AIDS Rev. 2007;9(1):3-15.
12. Sorli Redó ML, Knobel Freud H, Montero M, Jericó Alba C, Guelar Grimberg A, Pedro-Botet Montoya J. Sex influence in lipodystrophy of HIV-infected patients and its association with cardiovascular risk factors [in Spanish]. An Med Interna. 2007;24(4):168-172.
13. De Luca A, Murri R, Damiano F, Ammassari A, Antinori A. "Buffalo hump" in HIV-1 infection. Lancet. 1998;352(9124):320.
14. Dong K, Flynn MM, Dickinson BP, et al. Changes in body habitus in HIV(+) women after initiation of protease inhibitor therapy. Presented at the 12th World AIDS Conference; June 27-July 3, 1998; Geneva, Switzerland.
15. Palella FJ Jr, Chmiel JS, Riddler SA, et al. A novel pattern of lipoaccumulation in HIV-infected men. JAMA. 2006;296(7):766-768.
16. Guaraldi G, Orlando G, Squillace N, et al. Prevalence of and risk factors for pubic lipoma development in HIV-infected persons. J Acquir Immune Defic Syndr. 2007; 45(1):72-76.
17. Dank JP, Colven R. Protease inhibitor-associated angiolipomatosis. J Am Acad Dermatol. 2000;42(1 Pt 1):129-131.
18. Huang JS, Lee D, Becerra K, Santos R, Barber E, Mathews WC. Body image in men with HIV. AIDS Patient Care STDS. 2006;20(10):668-677.
19. Vázquez E. Banishing chipmunk cheeks and bullfrog neck. Treating these and other body changes from HIV drugs. Posit Aware. 2006;17(5):20-21.
20. Moyle GJ, Sabin CA, Cartledge J, et al; RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20(16):2043-2050.
21. Martin A, Smith DE, Carr A, et al; Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18(7): 1029-1036.
22. Viganò A, Brambilla P, Cafarelli L, et al. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz. Antivir Ther. 2007;12(3):297-302.
23. Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. Lipodystrophy in HIVinfected children is associated with high viral load and low CD4+ lymphocyte count and CD4+ lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr. 2001;27(1):30-34.
24. Bogner JR, Vielhauer V, Beckmann RA, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001;27(3): 237-244.